Infliximab efficacy in rheumatoid arthritis after an inadequate response to etanercept or adalimumab: results of a target-driven active switch study-Reference-Cited by-同舟云学术

Infliximab efficacy in rheumatoid arthritis after an inadequate response to etanercept or adalimumab: results of a target-driven active switch study

Published:2014-07-30 Issue:11 Volume:30 Page:2139-2149
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Fleischmann Roy¹,Goldman John A.²,Leirisalo-Repo Marjatta³,Zanetakis Ellen⁴,El-Kadi Hisham⁵,Kellner Herbert⁶,Bolce Rebecca⁷⁸,DeHoratius Raphael⁹¹⁰,Wang Jim¹¹,Decktor Dennis⁷¹²

Affiliation:

1. Metroplex Center for Clinical Research Dallas, TXUSA

2. Rheumatology, Atlanta Center for Clinical Research Atlanta, GAUSA

3. Department of Medicine, Helsinki University Central Hospital and University of Helsinki HelsinkiFinland

4. Rheumatology, Oklahoma Center for Arthritis Therapy and Research Inc. Tulsa, OKUSA

5. Rheumatology, Arthritis & Osteoporosis Associates PA Freehold, NJUSA

6. Center for Joint Diseases MunichGermany

7. Medical Affairs, Janssen Biotech Inc Horsham, PAUSA

8. Currently of Crescendo Bioscience San Francisco, CAUSA

9. Medical Affairs, Janssen Scientific Affairs, LLC Horsham, PAUSA

10. Department of Medicine, Jefferson Medical College, Thomas Jefferson University Philadelphia, PAUSA

11. Janssen Research & Development Belle Mead, NJUSA

12. Currently of Regeneron Pharmaceuticals, Inc. TarrytownNY, USA

Publisher

Informa Healthcare

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1185/03007995.2014.942416

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-Effectiveness of Biosimilars vs Leflunomide in Patients With Rheumatoid Arthritis;JAMA Network Open;2024-06-26

2. TNF and TNF receptors as therapeutic targets for rheumatic diseases and beyond;Nature Reviews Rheumatology;2023-08-04

3. Biophysical differences in IgG1 Fc-based therapeutics relate to their cellular handling, interaction with FcRn and plasma half-life;Communications Biology;2022-08-18

4. Infliximab Treatment Persistence among Japanese Patients with Chronic Inflammatory Diseases: A Retrospective Japanese Claims Data Study;Biological and Pharmaceutical Bulletin;2022-03-01

5. Cycling of tumor necrosis factor inhibitors versus switching to different mechanism of action therapy in rheumatoid arthritis patients with inadequate response to tumor necrosis factor inhibitors: a Bayesian network meta-analysis;Therapeutic Advances in Musculoskeletal Disease;2021-01